drugset / Trial / NCT00796133

A Phase 2, Dose-finding, Cross-over Study to Evaluate the Effect of a NES/E2 Transdermal Gel Delivery on Ovulation Suppression in Normal Ovulating Women

NCT00796133

Phase 2 Completed 18 enrolled Population Council
RandomizedCrossoverSingle-blindTreatment

Summary

This is a Phase 2, dose-finding, cross-over study for the purposes of evaluating the effect of a NES/E2 transdermal gel delivery on ovulation suppression in normal ovulating women.

Timeline

Start
2008-11
Primary completion
2014-01
Completion
2014-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Estradiol Other / unclassified 0.5 mg Other
Comparator Estradiol Other / unclassified 1 mg Other
Comparator Estradiol Other / unclassified 1.5 mg Other
Comparator Segesterone Acetate Small molecule 1.5 mg Other
Comparator Segesterone Acetate Small molecule 3 mg Other
Comparator Segesterone Acetate Small molecule 4.5 mg Other

Indications